Population Pharmacokinetic and Pharmacogenetic Analysis of Tacrolimus in Paediatric Liver Transplant Patients

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2013 Jun 7

PMID 23738951

Citations 14

Authors

Mariam H Abdel Jalil

Ahmed F Hawwa

Patrick J McKiernan

Michael D Shields

James C McElnay

Affiliations

Soon will be listed here.

Abstract

Aims: To build a population pharmacokinetic model that describes the apparent clearance of tacrolimus and the potential demographic, clinical and genetically controlled factors that could lead to inter-patient pharmacokinetic variability within children following liver transplantation.

Methods: The present study retrospectively examined tacrolimus whole blood pre-dose concentrations (n = 628) of 43 children during their first year post-liver transplantation. Population pharmacokinetic analysis was performed using the non-linear mixed effects modelling program (nonmem) to determine the population mean parameter estimate of clearance and influential covariates.

Results: The final model identified time post-transplantation and CYP3A5*1 allele as influential covariates on tacrolimus apparent clearance according to the following equation: TVCL = 12.9 x (Weight/13.2)(0.75) x EXP(-0.00158 x TPT) x EXP(0.428 x CYP3A5) where TVCL is the typical value for apparent clearance, TPT is time post-transplantation in days and the CYP3A5 is 1 where *1 allele is present and 0 otherwise. The population estimate and inter-individual variability (%CV) of tacrolimus apparent clearance were found to be 0.977 l h(-1) kg(-1) (95% CI 0.958, 0.996) and 40.0%, respectively, while the residual variability between the observed and predicted concentrations was 35.4%.

Conclusion: Tacrolimus apparent clearance was influenced by time post-transplantation and CYP3A5 genotypes. The results of this study, once confirmed by a large scale prospective study, can be used in conjunction with therapeutic drug monitoring to recommend tacrolimus dose adjustments that take into account not only body weight but also genetic and time-related changes in tacrolimus clearance.

Citing Articles

External assessment and refinement of a population pharmacokinetic model to guide tacrolimus dosing in pediatric heart transplant.

Rower J, McKnite A, Hong B, Daly K, Hope K, Cabrera A Pharmacotherapy. 2023; 43(7):650-658.

PMID: 37328271 PMC: 10527671. DOI: 10.1002/phar.2836.

Immune cell function assays in the diagnosis of infection in pediatric liver transplantation: an open-labeled, two center prospective cohort study.

Xue F, Gao W, Qin T, Wu C, Luo Y, Chen J Transl Pediatr. 2021; 10(2):333-343.

PMID: 33708519 PMC: 7944184. DOI: 10.21037/tp-20-256.

Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus.

Phan M, Chavan R, Beuttler R, Benipayo N, Magedman G, Buchbinder D Clin Transl Sci. 2021; 14(4):1303-1313.

PMID: 33503293 PMC: 8301588. DOI: 10.1111/cts.12982.

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.

Pinon M, De Nicolo A, Pizzol A, Antonucci M, DAvolio A, Serpe L Sci Rep. 2021; 11(1):443.

PMID: 33432012 PMC: 7801660. DOI: 10.1038/s41598-020-79574-7.

Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Hao G, Song L, Zhang D, Su L, Jacqz-Aigrain E, Zhao W Br J Clin Pharmacol. 2019; 86(2):274-284.

PMID: 31725919 PMC: 7015752. DOI: 10.1111/bcp.14174.

References

Li D, Lu W, Zhu J, Gao J, Lou Y, Zhang G . Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007; 32(5):505-15. DOI: 10.1111/j.1365-2710.2007.00850.x. View

Wallin J, Bergstrand M, Wilczek H, Nydert P, Karlsson M, Staatz C . Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit. 2011; 33(6):663-72. DOI: 10.1097/FTD.0b013e31823415cc. View

Hendrickson R, Karrer F, Wachs M, Slater K, Bak T, Kam I . Pediatric liver transplantation. Curr Opin Pediatr. 2004; 16(3):309-13. DOI: 10.1097/01.mop.0000127160.82531.77. View

Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T . Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006; 80(4):331-45. DOI: 10.1016/j.clpt.2006.06.008. View

Shuker N, Bouamar R, Weimar W, van Schaik R, van Gelder T, Hesselink D . ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta. 2011; 413(17-18):1326-37. DOI: 10.1016/j.cca.2011.09.040. View

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27(4):383-91. DOI: 10.1038/86882. View

Hawwa A, McElnay J . Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf. 2010; 10(1):9-22. DOI: 10.1517/14740338.2010.505600. View

Turolo S, Tirelli A, Ferraresso M, Ghio L, Belingheri M, Groppali E . Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep. 2011; 62(6):1159-69. DOI: 10.1016/s1734-1140(10)70378-9. View

10.

Sam W, Aw M, Quak S, Lim S, Charles B, Chan S . Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol. 2001; 50(6):531-41. PMC: 2015016. DOI: 10.1046/j.1365-2125.2000.00288.x. View

11.

Lindbom L, Ribbing J, Jonsson E . Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75(2):85-94. DOI: 10.1016/j.cmpb.2003.11.003. View

12.

Staatz C, Willis C, Taylor P, Lynch S, Tett S . Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003; 9(2):130-7. DOI: 10.1053/jlts.2003.50023. View

13.

Bonate P . Editorial to themed issue: Recent advances in cardiovascular pharmacokinetic-pharmacodynamic modeling and simulation. J Pharmacokinet Pharmacodyn. 2018; 45(3):353. DOI: 10.1007/s10928-018-9591-z. View

14.

Staatz C, Goodman L, Tett S . Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49(3):141-75. DOI: 10.2165/11317350-000000000-00000. View

15.

Garcia Sanchez M, Manzanares C, Blazquez A, Manzanares J, Urruzuno P, Medina E . Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet. 2001; 40(1):63-71. DOI: 10.2165/00003088-200140010-00005. View

16.

Arora-Gupta N, Davies P, McKiernan P, Kelly D . The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant. 2004; 8(2):145-50. DOI: 10.1046/j.1399-3046.2003.00132.x. View

17.

Antignac M, Barrou B, Farinotti R, Lechat P, Urien S . Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007; 64(6):750-7. PMC: 2198785. DOI: 10.1111/j.1365-2125.2007.02895.x. View

18.

Anderson B, Woollard G, Holford N . A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol. 2000; 50(2):125-34. PMC: 2014402. DOI: 10.1046/j.1365-2125.2000.00231.x. View

19.

Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View

20.

McDiarmid S, Colonna 2nd J, Shaked A, Vargas J, Ament M, Busuttil R . Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation. 1993; 55(6):1328-32. DOI: 10.1097/00007890-199306000-00022. View